Healthpeak Raises Full-Year Earnings Guidance Following Strong Q3 Performance
Healthpeak (DOC) raised its full-year earnings guidance by $0.05 per share during its third quarter 2026 earnings call, driven by strong operational momentum and improved occupancy trends. The company reported a significant rebound in life science lab occupancy, which has increased by 270 basis points year-to-date as demand diversifies to include artificial intelligence and robotics firms. Strategically, the company is leveraging distressed commercial real estate valuations to acquire lab buildings at discounts to replacement costs, aiming for stabilized yields of 9% to 10%. Additionally, Healthpeak has successfully executed nearly $2 billion in outpatient asset sales and recapitalizations at a 6% cap rate, allowing the firm to recycle capital into higher-yielding opportunities without issuing new equity.
Tickers: $DOC
Topics: acquisitions earnings guidance life science labs occupancy rates real estate